Danaher Co. (NYSE:DHR) Shares Purchased by Carderock Capital Management Inc.

Carderock Capital Management Inc. increased its holdings in shares of Danaher Co. (NYSE:DHRFree Report) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,404 shares of the conglomerate’s stock after acquiring an additional 391 shares during the quarter. Carderock Capital Management Inc.’s holdings in Danaher were worth $6,108,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Fairfield Bush & CO. raised its stake in Danaher by 10.9% during the first quarter. Fairfield Bush & CO. now owns 4,840 shares of the conglomerate’s stock worth $1,420,000 after purchasing an additional 475 shares during the period. Zions Bancorporation N.A. raised its stake in Danaher by 19.3% during the first quarter. Zions Bancorporation N.A. now owns 2,468 shares of the conglomerate’s stock worth $724,000 after purchasing an additional 400 shares during the period. Covestor Ltd raised its stake in shares of Danaher by 76.8% in the 1st quarter. Covestor Ltd now owns 495 shares of the conglomerate’s stock valued at $145,000 after acquiring an additional 215 shares during the period. NewEdge Advisors LLC raised its stake in shares of Danaher by 14.1% in the 1st quarter. NewEdge Advisors LLC now owns 31,530 shares of the conglomerate’s stock valued at $9,248,000 after acquiring an additional 3,897 shares during the period. Finally, Bridgewater Associates LP raised its stake in shares of Danaher by 135.9% in the 1st quarter. Bridgewater Associates LP now owns 35,270 shares of the conglomerate’s stock valued at $10,346,000 after acquiring an additional 20,320 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. Insiders sold 32,957 shares of company stock worth $8,265,802 in the last 90 days. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Down 0.7 %

NYSE DHR opened at $244.26 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00. The stock has a market capitalization of $180.88 billion, a PE ratio of 38.23, a price-to-earnings-growth ratio of 3.74 and a beta of 0.83. The firm has a 50 day moving average of $248.92 and a two-hundred day moving average of $230.38.

Danaher (NYSE:DHRGet Free Report) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company had revenue of $6.41 billion during the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter in the previous year, the business posted $2.87 EPS. The firm’s revenue was down 10.2% on a year-over-year basis. As a group, research analysts expect that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is 16.90%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on DHR shares. HSBC started coverage on shares of Danaher in a research note on Monday, December 18th. They issued a “hold” rating on the stock. Citigroup boosted their price target on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Raymond James boosted their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Barclays downgraded shares of Danaher from an “overweight” rating to an “equal weight” rating and set a $240.00 price target on the stock. in a research note on Wednesday, January 24th. Seven analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $266.00.

Get Our Latest Report on Danaher

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.